BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12191703)

  • 1. Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects.
    Gan SH; Ismail R; Wan Adnan WA; Wan Z
    J Pharm Biomed Anal; 2002 Sep; 30(2):189-195. PubMed ID: 12191703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
    Gan SH; Ismail R; Wan Adnan WA; Zulmi W
    Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
    Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
    Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.
    Borlak J; Hermann R; Erb K; Thum T
    Metabolism; 2003 Nov; 52(11):1439-43. PubMed ID: 14624403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population.
    Wang G; Zhang H; He F; Fang X
    Eur J Clin Pharmacol; 2006 Nov; 62(11):927-31. PubMed ID: 16960721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients.
    Dong H; Lu SJ; Zhang R; Liu DD; Zhang YZ; Song CY
    Eur J Clin Pharmacol; 2015 Jun; 71(6):681-686. PubMed ID: 25948472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
    Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia.
    Ismail R; Teh LK; Amir J; Alwi Z; Lopez CG
    J Clin Pharm Ther; 2003 Aug; 28(4):279-84. PubMed ID: 12911679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
    Fliegert F; Kurth B; Göhler K
    Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
    Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
    J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miotic action of tramadol is determined by CYP2D6 genotype.
    Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F
    Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
    Arafa MH; Atteia HH
    Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
    Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
    Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
    Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
    Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
    Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
    Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.